Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system
about
Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosisMAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomasIdentification of a novel L-serine analog that suppresses osteoclastogenesis in vitro and bone turnover in vivo.Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors.Hyperadiponectinemia enhances bone formation in mice.Transcriptional regulation of bone and joint remodeling by NFATSCFβ-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination.Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosisRANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss.Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathwayRANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis.Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.Inhibition of osteoclastogenesis by RNA interference targeting RANK.Pharmacological inhibition of intracellular calcium release blocks acid-induced bone resorption.Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human.The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic reviewThe molecular pathogenesis of osteosarcoma: a reviewEffects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice.Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unitA microRNA expression signature of osteoclastogenesisInterleukin-10 inhibits gram-negative-microbe-specific human receptor activator of NF-kappaB ligand-positive CD4+-Th1-cell-associated alveolar bone loss in vivoParathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer.Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclastsStauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression.Transient muscle paralysis degrades bone via rapid osteoclastogenesis.Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.Targeting polymer therapeutics to bone.Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity.TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activationFyn promotes proliferation, differentiation, survival and function of osteoclast lineage cellsThe Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivoα-Tocopheryl Succinate Inhibits Osteoclast Formation by Suppressing Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) Expression and Bone Resorption.Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice.IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression.Morphological Effects of Natural Products on Schizosaccharomyces pombe Measured by Imaging Flow CytometryIndividual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice.Epigenetic regulation of osteoclast differentiation.
P2860
Q26863571-9693A8B4-6458-457D-B7F7-4DB8A7AFEE46Q27665673-86B41EFB-C3C6-441A-9E96-76A749A5E3A4Q28393224-C8BE35B0-7B78-4410-8CD4-19B240BD7081Q33553478-9F014D66-FE88-4346-9DE0-A4BE02B328D9Q33719492-35193A63-EA04-47A2-9132-FB8756E1E1ABQ33795220-074DDC1D-2DA8-442B-A944-8A85C0CC231CQ33998768-9C26D311-50FE-4A22-BCEC-F39ACEE52439Q34100910-59A3FD40-360D-4AB2-BE92-43CE9C77B4B8Q34132873-6A7F082E-1B12-4F42-88E2-09D823100E2BQ34234347-71CFBC97-9FDC-4CD6-B59C-7012CD26DB63Q34278522-B7E5A33E-6EC1-416F-B04E-C45C42E6E214Q34279869-11B00018-AB1B-4413-A6A6-A32E9DB4ED50Q34298974-C1FADB72-E585-4D7F-B24A-E921A32B0908Q34334341-29F4A76A-3180-426D-98CA-3A4D6848D96DQ34389834-C6895E42-8983-4D21-9DE3-57C42BC180A6Q34501865-DDDA0132-EA6F-4CF8-963A-0E7CA2A46DC2Q34503355-6495EB9A-7363-4203-B3DD-BF1AC03D7081Q34571005-7922B9E2-2ABF-4F29-B634-125962342E98Q34629074-30318A1E-1CAD-4668-9ED5-2CCEDAB77951Q34746798-D35538C9-7C78-4030-A984-2C015951A72DQ34750367-CE2F9AAB-A1E0-4117-875F-F01A68C2A298Q34774013-B776121A-2171-4620-B24F-3A9DE0BE7253Q34975683-56BD6A5B-5FDC-4FA0-B80F-EB5D37B4FD2BQ35071181-FAE3B014-67B8-4CE6-9045-66E1E2C53999Q35378487-0408399F-6D52-49BC-88F8-EBB1959E4415Q35745300-3D43B27E-4DF9-460B-A75C-4CF40BBCF8D8Q35787758-C3DFBD8D-7E4F-49CB-8DA2-5E1741F93EA5Q35868608-E0746F4D-08F3-4EDB-B6E3-AE231A88B048Q35951743-2BCFEF9E-1276-4D27-AC62-9C5A14B19F29Q36071793-FFD35A18-2B78-406B-AB91-95ECC72BB81CQ36636031-F3BA7372-1A1E-4465-AC39-79E9748533D7Q36871656-16766AC0-09C3-4F4B-BA8C-6C5083A4B42CQ37035480-2490CCD1-6CD9-44B3-9C83-120926129C56Q37114842-95E00E80-4BBA-4786-A5D8-66197EC994A6Q37192084-CED5F112-92D7-4666-B4B5-51E54DCA0FD2Q37200578-8E6D9E20-1797-4C1D-B540-E66B2603E7ABQ37342418-BBDC58E7-C887-46C1-B582-5E244B75E488Q37642172-CF753E1F-BB94-44A6-AE1C-869F0E359E63Q37720404-613163D4-8EF1-4F02-B8B2-3A64D439A579Q37968675-ECB22429-E0F7-4449-BB54-3731CD050351
P2860
Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@ast
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@en
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@nl
type
label
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@ast
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@en
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@nl
prefLabel
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@ast
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@en
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@nl
P2093
P2860
P1476
Role of RANKL in physiological ...... he RANKL-RANK signaling system
@en
P2093
Kozo Nakamura
Naoyuki Takahasi
Sakae Tanaka
Tatsuo Suda
P2860
P356
10.1111/J.0105-2896.2005.00327.X
P407
P577
2005-12-01T00:00:00Z